ROPINIROLE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

ROPINIROLE (ROPINIROLE HYDROCHLORIDE)

Saadav alates:

SANIS HEALTH INC

ATC kood:

N04BC04

INN (Rahvusvaheline Nimetus):

ROPINIROLE

Annus:

1MG

Ravimvorm:

TABLET

Koostis:

ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 1MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0132618003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2010-06-18

Toote omadused

_ _
_ROPINIROLE 0.25 mg, 1 mg, Tablets _
_Page 1 of 53_
PRODUCT MONOGRAPH
Pr
ROPINIROLE
Ropinirole Tablets, USP
0.25 mg and 1 mg ropinirole (as ropinirole hydrochloride)
Antiparkinsonian Agent / Dopamine Agonist
Sanis Health Inc.
1 President’s Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Revision:
February 10, 2021
Submission Control No.: 244016
_ _
_ROPINIROLE 0.25 mg, 1 mg Tablets _
_Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
21
DOSAGE AND ADMINISTRATION
.............................................................................
23
OVERDOSAGE
...............................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 25
STORAGE AND STABILITY
.........................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 29
PART II: SCIENTIFIC INFORMATION
..............................................................................
30
PHARMACEUTICAL INFORMATION
.........................................................................
30
CLINICAL TRIALS
...............................................................................